rden2delta30-7169
Vaccineexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01931176)
Timeline
Indications
Mechanism of action
- Dengue virusImmunity, active
Dengue virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rden2delta30-7169
- rden2δ30-7169
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06908018 | Early Phase 1 (Phase 1) | Sep 30, 2025 | Johns Hopkins University, Mahidol University, National Institutes of Health (NIH) |
| NCT05476757 | Early Phase 1 (Phase 1) | Aug 31, 2022 | Mahidol University |
| NCT05229354 | Phase 2 | Dec 11, 2021 | International Center for Diarrheal Disease Research, University of Vermont |
| NCT03416036 | Phase 1 | Nov 28, 2017 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02433652 | Phase 1 | Sep 1, 2015 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), University of Vermont |
| NCT02392325 | Phase 1 | Mar 1, 2015 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01931176 | Phase 1 | Jun 1, 2013 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 5 | 0 | 1 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 4 | 4 | 1 | 2013 |
| Mahidol University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| University of Vermont | Academic/Hospital | 2 | 1 | 2 | 2015 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2025 |
6 organizations
Page 1 / 1